Physician profile
Scott E Hirsch
NPI 1851514434
$53,770.87
in general payments reported to CMS, 2019-2025
30 companies · $31K in 2025
The $31K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $122 · 2021: $376 · 2022: $1,519 · 2023: $11K · 2024: $9,992 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Honoraria: $17K · Food and Beverage: $9,545 · Consulting Fee: $2,000 · Travel and Lodging: $475 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,300.00 |
| Honoraria | $16,775.00 |
| Food and Beverage | $9,545.07 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $474.90 |
| Education | $409.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,135.46 | 2021-2025 | |
| Axsome Therapeutics, INC. | $20,384.94 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $1,622.33 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $909.84 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $813.28 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $775.14 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $633.89 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $592.28 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $332.01 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $307.94 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $299.12 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Jazz Pharmaceuticals INC. | $297.38 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $276.65 | 2022-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $246.06 | 2021-2025 | Trintellix |
| Corium, LLC | $197.64 | 2022-2025 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $106.24 | 2023-2025 | Aplenzin, Wellbutrin, Addyi |
| Neuronetics, INC. | $99.17 | 2022 | |
| Avanir Pharmaceuticals, INC. | $93.63 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.99 | 2025 | Rejoyn |
| Neos Therapeutics, LP | $83.16 | 2023-2024 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $66.54 | 2024-2025 | Relexxii |
| Sunovion Pharmaceuticals INC. | $64.98 | 2022 | |
| Acadia Pharmaceuticals INC | $62.43 | 2025 | Nuplazid |
| Harmony Biosciences LLC | $51.98 | 2021-2022 | |
| Tris Pharma INC | $48.96 | 2024-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $48.91 | 2022 | |
| Ironshore Pharmaceuticals INC. | $43.10 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $39.48 | 2022-2024 | Quviviq |
| Tempus Ai, INC | $26.31 | 2024 | |
| Glaxosmithkline, LLC. | $20.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.